Zhitong Finance App News, Yisheng Pharmaceutical (002566.SZ) issued an announcement. On July 1, 2026, the company received the “Notice of Adopting Risk Control Measures” issued by the Jilin Drug Administration [2026] T02. After receiving the notice, the company attached great importance to it and immediately set up a special rectification working group to organize management and relevant business departments to list the problems against the notice, sort out and dig deeper into the root causes of the problems item by item, formulate a special rectification plan, and clarify the rectification tasks, responsible subjects, and rectification time frame. The company strictly complies with regulatory requirements to carry out various rectification work, implement rectification of existing defects item by item, improve management systems, strengthen personnel training, and make up for internal control shortcomings. Today, the company received the “Notice of Cancellation of Risk Control Measures” from the Jilin Drug Administration [2026] T02. After on-site inspection, it was confirmed that potential safety hazards have been ruled out and agreed to lift the risk control measures.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.